Polycystic Kidney Disease Overview

Polycystic kidney disease (PKD) is a genetic disease (passed from an affected parent to their child) causing uncontrolled growth of cysts in the kidney eventually leading to kidney failure. While the disease affects all races and ethnicities equally, data suggests African Americans suffer worse outcomes due to delayed diagnosis, slower referrals to nephrology specialists than their whitecounterparts, and earlier progression to end-stage renal disease as a result.

“Polycystic Kidney Disease Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polycystic Kidney Disease Market. 

The Polycystic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Polycystic Kidney Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Polycystic Kidney Disease treatment therapies with a considerable amount of success over the years. Polycystic Kidney Disease Key players such as – AmMax Bio, AceLink Therapeutics, Kadmon Pharmaceuticals, Galapagos NV, Centessa Pharmaceuticals, Reata Pharmaceuticals, and others, are developing therapies for the Polycystic Kidney Disease treatment 

• Polycystic Kidney Disease Emerging therapies such as – AMB-05X, AL01211, Tesevatinib, GLPG2737, Lixivaptan, Bardoxolone methyl, and others are expected to have a significant impact on the Polycystic Kidney Disease market in the coming years.   
• In May 2019, Reata Pharmaceuticals initiated a Phase III trial of Bardoxolone Methyl in patients with autosomal dominant polycystic kidney disease
• The FDA and European Commission had granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”) 

Polycystic Kidney Disease Pipeline Therapeutics Assessment

• Polycystic Kidney Disease Assessment by Product Type
• Polycystic Kidney Disease By Stage and Product Type
• Polycystic Kidney Disease Assessment by Route of Administration
• Polycystic Kidney Disease By Stage and Route of Administration
• Polycystic Kidney Disease Assessment by Molecule Type
• Polycystic Kidney Disease by Stage and Molecule Type 

DelveInsight’s Polycystic Kidney Disease Report covers around 22+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Polycystic Kidney Disease Drugs Under Different Phases of Clinical Development Include: 

• AMB-05X: AmMax Bio
• AL01211: AceLink Therapeutics
• Tesevatinib: Kadmon Pharmaceuticals
• GLPG2737: Galapagos NV
• Lixivaptan: Centessa Pharmaceuticals   
• Bardoxolone methyl: Reata Pharmaceuticals 

Polycystic Kidney Disease Pipeline Analysis:

The Polycystic Kidney Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Polycystic Kidney Disease treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycystic Kidney Disease Treatment.
• Polycystic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Polycystic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycystic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Polycystic Kidney Disease product details are provided in the report. Download the Polycystic Kidney Disease pipeline report to learn more about the emerging Polycystic Kidney Disease therapies

Polycystic Kidney Disease Pipeline Market Drivers

• Increase in the number of research and development activities
• Rising investment for the development of advanced technologies

Polycystic Kidney Disease Pipeline Market Barriers

• High cost associated with the Polycystic Kidney Disease treatment
• Lack of healthcare infrastructure in developing economies

Get a Free Sample PDF Report to know more about Polycystic Kidney Disease Pipeline Assessment

Scope of Polycystic Kidney Disease Pipeline Drug Insight    

• Coverage: Global
• Key Polycystic Kidney Disease Companies: AmMax Bio, AceLink Therapeutics, Kadmon Pharmaceuticals, Galapagos NV, Centessa Pharmaceuticals, Reata Pharmaceuticals, and others
• Key Polycystic Kidney Disease Therapies: AMB-05X, AL01211, Tesevatinib, GLPG2737, Lixivaptan, Bardoxolone methyl, and others
• Polycystic Kidney Disease Therapeutic Assessment: Polycystic Kidney Disease current marketed and Polycystic Kidney Disease emerging therapies
• Polycystic Kidney Disease Market Dynamics:  Polycystic Kidney Disease market drivers and Polycystic Kidney Disease market barriers 

Request for Sample PDF Report for Polycystic Kidney Disease Pipeline Assessment and clinical trials 

Table of Contents

Download Sample PDF Report to know more about Polycystic Kidney Disease drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com